Pressure Rises On Vertex and NHS England To Reach Orkambi Deal As Parliamentary Scrutiny Increases
Executive Summary
Vertex and NHS England are under pressure to strike a deal on cystic fibrosis drug Orkambi after UK a parliamentary debate put health technology appraisal body NICE under the spotlight.
You may also be interested in...
UK Inquiry Schedules Public Hearing On Availability Of Vertex’s Orkambi
In the next stage of the UK inquiry into the availability of Vertex’s cystic fibrosis drug Orkambi on England’s National Health Service, a public hearing will take place in March.
UK Inquiry Into ‘Unfair’ Orkambi Pricing Risks Pricing Confidentiality
The UK government has criticized Vertex for the company’s approach to pricing its cystic fibrosis drug Orkambi. In the meantime, a parliamentary inquiry that could expose sensitive pricing details moves forward.
NHS England Offers Vertex Final Orkambi Deal
The increasingly public row between Vertex and NHS England continues as NHS England claims it has offered Vertex the “largest ever financial commitment of its type” in its 70-year history. Meanwhile, Vertex has revealed that the NHS has offered a price that is significantly lower than the list price.